{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T16:13:26Z","timestamp":1783008806833,"version":"3.54.5"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T00:00:00Z","timestamp":1582761600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T00:00:00Z","timestamp":1582761600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"National Science and Technology Major Projects for \u201cMajor New Drugs Innovation and Development\u201d","award":["2017ZX09304028-006"],"award-info":[{"award-number":["2017ZX09304028-006"]}]},{"DOI":"10.13039\/501100013315","name":"Science and Technology Service Network Plan","doi-asserted-by":"publisher","award":["2017ZX09101001"],"award-info":[{"award-number":["2017ZX09101001"]}],"id":[{"id":"10.13039\/501100013315","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006734","name":"Instituto Nacional de Ci\u00eancia e Tecnologia de F\u00e1rmacos e Medicamentos","doi-asserted-by":"crossref","award":["2018ZX09201014"],"award-info":[{"award-number":["2018ZX09201014"]}],"id":[{"id":"10.13039\/501100006734","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Key R&D Program of China","award":["2016YFC0904900"],"award-info":[{"award-number":["2016YFC0904900"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81673509"],"award-info":[{"award-number":["81673509"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81573504"],"award-info":[{"award-number":["81573504"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"crossref","award":["7171012"],"award-info":[{"award-number":["7171012"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s12325-020-01259-4","type":"journal-article","created":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T11:04:27Z","timestamp":1582801467000},"page":"1496-1521","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Efficacy and Safety of PCSK9 Monoclonal Antibodies in Patients at High Cardiovascular Risk: An Updated Systematic Review and Meta-Analysis of 32 Randomized Controlled Trials"],"prefix":"10.1007","volume":"37","author":[{"given":"Guangyan","family":"Mu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Litong","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjun","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiufen","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zining","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanxu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimin","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,27]]},"reference":[{"key":"1259_CR1","doi-asserted-by":"crossref","unstructured":"Collins R, Armitage J, Parish S, Sleigh P, Peto R, Heart Protection Study Collaborative Group. MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005\u201316.","DOI":"10.1016\/S0140-6736(03)13636-7"},{"key":"1259_CR2","doi-asserted-by":"crossref","unstructured":"Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73:e285\u2013350.","DOI":"10.1016\/j.jacc.2018.11.004"},{"key":"1259_CR3","first-page":"1","volume":"2019","author":"F Mach","year":"2019","unstructured":"Mach F, Baigent C, Catapano AL, et al. ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019;2019:1\u201378.","journal-title":"Eur Heart J"},{"key":"1259_CR4","doi-asserted-by":"crossref","first-page":"846","DOI":"10.5551\/jat.GL2017","volume":"25","author":"M Kinoshita","year":"2018","unstructured":"Kinoshita M, Yokote K, Arai H, et al. Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017. J Atheroscler Thromb. 2018;25:846\u2013984.","journal-title":"J Atheroscler Thromb"},{"key":"1259_CR5","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12916-015-0358-8","volume":"13","author":"X-L Zhang","year":"2015","unstructured":"Zhang X-L, Zhu Q-Q, Zhu L, et al. Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. BMC Med. 2015;13:123.","journal-title":"BMC Med"},{"key":"1259_CR6","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1093\/eurheartj\/ehx450","volume":"39","author":"BA Ference","year":"2018","unstructured":"Ference BA, Cannon CP, Landmesser U, L\u00fcscher TF, Catapano AL, Ray KK. Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration. Eur Heart J. 2018;39:2540\u20135.","journal-title":"Eur Heart J"},{"key":"1259_CR7","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.atherosclerosis.2018.07.032","volume":"276","author":"GR Thompson","year":"2018","unstructured":"Thompson GR. Atherosclerosis in cholesterol-fed rabbits and in homozygous and heterozygous LDL receptor-deficient humans. Atherosclerosis. 2018;276:148\u201354.","journal-title":"Atherosclerosis"},{"key":"1259_CR8","doi-asserted-by":"crossref","unstructured":"Ridker PM, Tardif J-C, Amarenco P, et al. Lipid-reduction variability and antidrug-antibody formation with bococizumab. N Engl J Med. 2017;376:1517\u201326.","DOI":"10.1056\/NEJMoa1614062"},{"key":"1259_CR9","first-page":"229","volume":"109","author":"Y-S Zhang","year":"2018","unstructured":"Zhang Y-S, Hao Y-H, Luo H-L, Xie B-C, Fu J-Y, Zhou Z-K. Comparisons of three different doses of alirocumab application in patients with hypercholesterolemia: a meta-analysis. Minerva Med. 2018;109:229\u201338.","journal-title":"Minerva Med"},{"key":"1259_CR10","doi-asserted-by":"publisher","unstructured":"Karatasakis A, Danek BA, Karacsonyi J, et al. Effect of PCSK9 inhibitors on clinical outcomes in patients with hypercholesterolemia: a meta\u2010analysis of 35 randomized controlled trials. J Am Heart Assoc. 2017;6. https:\/\/doi.org\/10.1161\/JAHA.117.006910 .","DOI":"10.1161\/JAHA.117.006910"},{"key":"1259_CR11","doi-asserted-by":"publisher","unstructured":"Toth PP, Worthy G, Gandra SR, et al. Systematic review and network meta-analysis on the efficacy of evolocumab and other therapies for the management of lipid levels in hyperlipidemia. J Am Heart Assoc. 2017;6. https:\/\/doi.org\/10.1161\/JAHA.116.005367.","DOI":"10.1161\/JAHA.116.005367"},{"key":"1259_CR12","doi-asserted-by":"crossref","first-page":"81","DOI":"10.18433\/J36C8N","volume":"20","author":"SM Eslami","year":"2017","unstructured":"Eslami SM, Nikfar S, Ghasemi M, Abdollahi M. Does evolocumab, as a PCSK9 inhibitor, ameliorate the lipid profile in familial hypercholesterolemia patients? A meta-analysis of randomized controlled trials. J Pharm Pharm Sci. 2017;20:81\u201396.","journal-title":"J Pharm Pharm Sci"},{"key":"1259_CR13","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s40618-019-01019-4","volume":"42","author":"I Dicembrini","year":"2019","unstructured":"Dicembrini I, Giannini S, Ragghianti B, Mannucci E, Monami M. Effects of PCSK9 inhibitors on LDL cholesterol, cardiovascular morbidity and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials. J Endocrinol Invest. 2019;42:1029\u201339.","journal-title":"J Endocrinol Invest"},{"key":"1259_CR14","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.phrs.2019.03.021","volume":"143","author":"M Casula","year":"2019","unstructured":"Casula M, Olmastroni E, Boccalari MT, Tragni E, Pirillo A, Catapano AL. Cardiovascular events with PCSK9 inhibitors: an updated meta-analysis of randomised controlled trials. Pharmacol Res. 2019;143:143\u201350.","journal-title":"Pharmacol Res"},{"key":"1259_CR15","doi-asserted-by":"publisher","unstructured":"Guedeney P, Giustino G, Sorrentino S, et al. Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials. Eur Heart J. 2019. https:\/\/doi.org\/10.1093\/eurheartj\/ehz430.","DOI":"10.1093\/eurheartj\/ehz430"},{"key":"1259_CR16","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/j.cjca.2018.04.002","volume":"34","author":"RD Turgeon","year":"2018","unstructured":"Turgeon RD, Tsuyuki RT, Gyenes GT, Pearson GJ. Cardiovascular efficacy and safety of PCSK9 inhibitors: systematic review and meta-analysis including the ODYSSEY OUTCOMES trial. Can J Cardiol. 2018;34:1600\u20135.","journal-title":"Can J Cardiol"},{"key":"1259_CR17","doi-asserted-by":"crossref","unstructured":"Du H, Li X, Su N, et al. Proprotein convertase subtilisin\/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and meta-analysis. Heart. 2019;105:1149\u201359.","DOI":"10.1136\/heartjnl-2019-314763"},{"key":"1259_CR18","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379:2097\u2013107.","journal-title":"N Engl J Med"},{"key":"1259_CR19","unstructured":"NCT02715726. Evaluation of alirocumab versus ezetimibe on top of statin in Asia in high cardiovascular risk patients with hypercholesterolemia (ODYSSEY EAST).  https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02715726?term=NCT02715726&draw=2&rank=1."},{"key":"1259_CR20","doi-asserted-by":"crossref","unstructured":"Rosenson RS, Daviglus ML, Handelsman Y, et al. Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study. Diabetologia. 2019;62:948\u201358.","DOI":"10.1007\/s00125-019-4856-7"},{"key":"1259_CR21","doi-asserted-by":"crossref","unstructured":"Lorenzatti AJ, Eliaschewitz FG, Chen Y, et al. Randomised study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: primary results of the BERSON clinical trial. Diabetes Obes Metab. 2019;21:1455\u201363.","DOI":"10.1111\/dom.13680"},{"key":"1259_CR22","doi-asserted-by":"crossref","first-page":"5253","DOI":"10.1210\/jc.2018-02703","volume":"104","author":"D M\u00fcller-Wieland","year":"2019","unstructured":"M\u00fcller-Wieland D, Rader DJ, Moriarty PM, et al. Efficacy and safety of alirocumab 300\u00a0mg every 4 weeks in individuals with type 2 diabetes on maximally tolerated statin. J Clin Endocrinol Metab. 2019;104:5253\u201362.","journal-title":"J Clin Endocrinol Metab"},{"key":"1259_CR23","doi-asserted-by":"crossref","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.","DOI":"10.1371\/journal.pmed.1000097"},{"key":"1259_CR24","unstructured":"Higgins JP, Green S, editors. Cochrane handbook for systematic reviews of interventions. Version 5. The Cochrane Collaboration. Hoboken, NJ: Wiley; 2011."},{"key":"1259_CR25","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","volume":"18","author":"WT Friedewald","year":"1972","unstructured":"Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499\u2013502.","journal-title":"Clin Chem"},{"key":"1259_CR26","doi-asserted-by":"crossref","unstructured":"Stein EA, Turner T, Plunkett N, Zhou R, Fritz C. Friedewald formula significantly underestimates LDL cholesterol compared to preparative ultracentrifugation below 70 mg\/dl leading to overestimation of the LDL cholesterol reduction for new drugs in development. J Am Coll Cardiol. 2014;63:A1457.","DOI":"10.1016\/S0735-1097(14)61457-1"},{"key":"1259_CR27","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014;14:135.","journal-title":"BMC Med Res Methodol"},{"key":"1259_CR28","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177\u201388.","journal-title":"Control Clin Trials"},{"key":"1259_CR29","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1177\/0272989X05282643","volume":"25","author":"AE Ades","year":"2005","unstructured":"Ades AE, Lu G, Higgins JPT. The interpretation of random-effects meta-analysis in decision models. Med Decis Making. 2005;25:646\u201354.","journal-title":"Med Decis Making"},{"key":"1259_CR30","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360.","journal-title":"BMJ"},{"key":"1259_CR31","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","volume":"50","author":"HC Bucher","year":"1997","unstructured":"Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50:683\u201391.","journal-title":"J Clin Epidemiol"},{"key":"1259_CR32","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.medcli.2012.09.013","volume":"140","author":"F Catal\u00e1-L\u00f3pez","year":"2013","unstructured":"Catal\u00e1-L\u00f3pez F, Tob\u00edas A. S\u00edntesis de la evidencia cl\u00ednica y metaan\u00e1lisis en red con comparaciones indirectas. Med Clin (Barc). 2013;140:182\u20137.","journal-title":"Med Clin (Barc)"},{"key":"1259_CR33","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/bmj.326.7382.219","volume":"326","author":"DG Altman","year":"2003","unstructured":"Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ. 2003;326:219.","journal-title":"BMJ"},{"key":"1259_CR34","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629\u201334.","journal-title":"BMJ"},{"key":"1259_CR35","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","volume":"50","author":"CB Begg","year":"1994","unstructured":"Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088\u2013101.","journal-title":"Biometrics"},{"key":"1259_CR36","first-page":"89","volume":"95","author":"S Duval","year":"2000","unstructured":"Duval S, Tweedie R. A nonparametric \u201ctrim and fill\u201d method of accounting for publication bias in meta-analysis. J Am Stat Assoc. 2000;95:89\u201398.","journal-title":"J Am Stat Assoc"},{"key":"1259_CR37","unstructured":"Pedroza-Tob\u00edas A. Assessing the influence of a single study in the meta-analysis estimate. Stata Technol Bull. 1999;8(47)."},{"key":"1259_CR38","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/eurheartj\/ehv028","volume":"36","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Cariou B, Blom D, et al. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J. 2015;36:1186\u201394.","journal-title":"Eur Heart J"},{"key":"1259_CR39","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","volume":"372","author":"JG Robinson","year":"2015","unstructured":"Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1489\u201399.","journal-title":"N Engl J Med"},{"key":"1259_CR40","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","volume":"9","author":"PM Moriarty","year":"2015","unstructured":"Moriarty PM, Thompson PD, Cannon CP, et al. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol. 2015;9:758\u201369.","journal-title":"J Clin Lipidol"},{"issue":"906\u2013915","key":"1259_CR41","first-page":"e13","volume":"169","author":"DJ Kereiakes","year":"2015","unstructured":"Kereiakes DJ, Robinson JG, Cannon CP, et al. Efficacy and safety of the proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study. Am Heart J. 2015;169(906\u2013915):e13.","journal-title":"Am Heart J"},{"key":"1259_CR42","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1210\/jc.2015-1520","volume":"100","author":"H Bays","year":"2015","unstructured":"Bays H, Gaudet D, Weiss R, et al. Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial. J Clin Endocrinol Metab. 2015;100:3140\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"1259_CR43","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","volume":"385","author":"FJ Raal","year":"2015","unstructured":"Raal FJ, Honarpour N, Blom DJ, et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385:341\u201350.","journal-title":"Lancet"},{"key":"1259_CR44","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.amjcard.2015.10.021","volume":"117","author":"A Kiyosue","year":"2016","unstructured":"Kiyosue A, Honarpour N, Kurtz C, Xue A, Wasserman SM, Hirayama A. A phase 3 study of evolocumab (AMG 145) in statin-treated Japanese patients at high cardiovascular risk. Am J Cardiol. 2016;117:40\u20137.","journal-title":"Am J Cardiol"},{"key":"1259_CR45","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1253\/circj.CJ-16-0387","volume":"80","author":"T Teramoto","year":"2016","unstructured":"Teramoto T, Kobayashi M, Tasaki H, et al. Efficacy and safety of alirocumab in Japanese patients with heterozygous familial hypercholesterolemia or at high cardiovascular risk with hypercholesterolemia not adequately controlled with statins\u2014ODYSSEY JAPAN randomized controlled trial. Circ J. 2016;80:1980\u20137.","journal-title":"Circ J"},{"key":"1259_CR46","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","volume":"316","author":"SJ Nicholls","year":"2016","unstructured":"Nicholls SJ, Puri R, Anderson T, et al. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. JAMA. 2016;316:2373\u201384.","journal-title":"JAMA"},{"key":"1259_CR47","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.atherosclerosis.2015.11.010","volume":"244","author":"M Farnier","year":"2016","unstructured":"Farnier M, Jones P, Severance R, et al. Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: the ODYSSEY OPTIONS II randomized trial. Atherosclerosis. 2016;244:138\u201346.","journal-title":"Atherosclerosis"},{"key":"1259_CR48","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s10557-016-6685-y","volume":"30","author":"HN Ginsberg","year":"2016","unstructured":"Ginsberg HN, Rader DJ, Raal FJ, et al. Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia and LDL-C of 160\u00a0mg\/dl or higher. Cardiovasc Drugs Ther. 2016;30:473\u201383.","journal-title":"Cardiovasc Drugs Ther"},{"key":"1259_CR49","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1093\/eurheartj\/ehw388","volume":"37","author":"PM Moriarty","year":"2016","unstructured":"Moriarty PM, Parhofer KG, Babirak SP, et al. Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial. Eur Heart J. 2016;37:3588\u201395.","journal-title":"Eur Heart J"},{"key":"1259_CR50","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1111\/dom.13114","volume":"19","author":"LA Leiter","year":"2017","unstructured":"Leiter LA, Cariou B, M\u00fcller-Wieland D, et al. Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: the ODYSSEY DM-INSULIN randomized trial. Diabetes Obes Metab. 2017;19:1781\u201392.","journal-title":"Diabetes Obes Metab"},{"key":"1259_CR51","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713\u201322.","journal-title":"N Engl J Med"},{"key":"1259_CR52","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1056\/NEJMoa1701488","volume":"376","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Revkin J, Amarenco P, et al. Cardiovascular efficacy and safety of bococizumab in high-risk patients. N Engl J Med. 2017;376:1527\u201339.","journal-title":"N Engl J Med"},{"issue":"162\u2013172","key":"1259_CR53","first-page":"e6","volume":"12","author":"KK Koh","year":"2018","unstructured":"Koh KK, Nam CW, Chao T-H, et al. A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT). J Clin Lipidol. 2018;12(162\u2013172):e6.","journal-title":"J Clin Lipidol"},{"key":"1259_CR54","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.jacl.2018.03.088","volume":"12","author":"PM Ridker","year":"2018","unstructured":"Ridker PM, Rose LM, Kastelein JJP, et al. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: results from the SPIRE randomized trials of bococizumab. J Clin Lipidol. 2018;12:958\u201365.","journal-title":"J Clin Lipidol"},{"key":"1259_CR55","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(12)60771-5","volume":"380","author":"EA Stein","year":"2012","unstructured":"Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727\/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012;380:29\u201336.","journal-title":"Lancet"},{"key":"1259_CR56","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.112.144055","volume":"126","author":"F Raal","year":"2012","unstructured":"Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia. Circulation. 2012;126:2408\u201317.","journal-title":"Circulation"},{"key":"1259_CR57","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1253\/circj.CJ-14-0130","volume":"78","author":"A Hirayama","year":"2014","unstructured":"Hirayama A, Honarpour N, Yoshida M, et al. Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk\u2013primary results from the phase 2 YUKAWA study. Circ J. 2014;78:1073\u201382.","journal-title":"Circ J"},{"key":"1259_CR58","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","volume":"385","author":"FJ Raal","year":"2015","unstructured":"Raal FJ, Stein EA, Dufour R, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385:331\u201340.","journal-title":"Lancet"},{"key":"1259_CR59","first-page":"2996","volume":"36","author":"JJP Kastelein","year":"2015","unstructured":"Kastelein JJP, Ginsberg HN, Langslet G, et al. ODYSSEY FH I and FH II: 78\u00a0week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J. 2015;36:2996\u20133003.","journal-title":"Eur Heart J"},{"key":"1259_CR60","doi-asserted-by":"crossref","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670\u201381.","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"1259_CR61","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3109\/07853890.2011.582135","volume":"44","author":"CR Sirtori","year":"2012","unstructured":"Sirtori CR, Mombelli G, Triolo M, Laaksonen R. Clinical response to statins: mechanism(s) of variable activity and adverse effects. Ann Med. 2012;44:419\u201332.","journal-title":"Ann Med"},{"key":"1259_CR62","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1517\/14656560903376186","volume":"10","author":"TR Bates","year":"2009","unstructured":"Bates TR, Connaughton VM, Watts GF. Non-adherence to statin therapy: a major challenge for preventive cardiology. Expert Opin Pharmacother. 2009;10:2973\u201385.","journal-title":"Expert Opin Pharmacother"},{"key":"1259_CR63","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1161\/CIRCULATIONAHA.116.023007","volume":"134","author":"D Nanchen","year":"2016","unstructured":"Nanchen D, Gencer B, Muller O, et al. Prognosis of patients with familial hypercholesterolemia after acute coronary syndromes. Circulation. 2016;134:698\u2013709.","journal-title":"Circulation"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01259-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-020-01259-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01259-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T00:49:38Z","timestamp":1614300578000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-020-01259-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,27]]},"references-count":63,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["1259"],"URL":"https:\/\/doi.org\/10.1007\/s12325-020-01259-4","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,27]]},"assertion":[{"value":"29 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}